MYH9 and head and neck cancer: For example, You et al. [17] discovered that the actomyosin cytoskeleton component myosin heavy chain 9 (MYH9) facilitated radio-resistance in head and neck cancer call by activating NRF2 and modulating cellular ROS levels.